Alcohol use disorder (AUD) and opioid use disorder (OUD) are chronic, relapsing medical conditions with significant morbidity and mortality. While psychological and social interventions remain the cornerstone of addiction treatment — including structured counselling, motivational interviewing, peer support, and residential programmes — pharmacotherapy plays a documented, evidence-based role in improving abstinence rates, reducing relapse, and lowering the lethality of use when relapse occurs.
The efficacy of FDA-approved pharmacotherapies for alcohol use disorder (acamprosate, naltrexone, and disulfiram) is well-established in randomised controlled trial evidence, yet these medications remain dramatically underutilised in clinical practice relative to their evidence base. Estimates suggest that fewer than 10% of individuals diagnosed with AUD in the US receive any FDA-approved pharmacotherapy. This treatment gap represents a substantial public health failure. Similarly, naltrexone and buprenorphine-based therapies for opioid use disorder are evidence-based yet underprescribed compared to the scale of the opioid epidemic.
A critical professional consensus principle: pharmacotherapy for dependence disorders is most effective as part of a comprehensive, structured addiction treatment programme that includes psychological and behavioural components. Medication alone, without engagement in treatment, produces inferior outcomes compared to combined approaches. Patient motivation and informed consent are prerequisites for pharmacotherapy — particularly for disulfiram, where the patient must fully understand and accept the consequences of taking the medication (the disulfiram-ethanol reaction, or DER) before initiating therapy.
Principal pharmacotherapy categories for dependence disorders include:
- Aversion Therapy (Antabuse / Disulfiram): ALDH inhibitor causing severe disulfiram-ethanol reaction (DER) with any alcohol exposure. Acts as a pharmacological deterrent. Requires informed consent, medical supervision, and sobriety for ≥12 hours before first dose. Not suitable for all patients.
- Opioid Antagonists (Naltrexone / ReVia; Naltrexone ER injectable / Vivitrol; Naloxone): Mu-opioid receptor antagonist blocking the rewarding and euphoric effects of opioids; also reduces craving and alcohol reinforcement. For AUD and OUD. Must confirm opioid-free status before starting to avoid precipitating acute withdrawal.
- Glutamate Modulators (Acamprosate / Campral): Reduces neurochemical imbalance associated with alcohol withdrawal and post-acute abstinence syndrome. Does not cause DER, not metabolised by liver — useful when hepatic function is compromised.
- Partial Opioid Agonists (Buprenorphine/Naloxone / Suboxone): Used for opioid use disorder maintenance therapy. High-affinity partial agonist reduces withdrawal and craving without full agonist euphoria; naloxone component deters intravenous misuse. Requires DEA waiver (DATA-waived) in the US.
Lucas Clinic provides detailed information about the dependence medications available in our inventory: